摘要
【目的】评价白蛋白结合型紫杉醇联合铂类方案治疗中国晚期黑色素瘤患者的疗效与安全性。【方法】38例晚期恶性黑色素瘤患者接受白蛋白结合型紫杉醇[100 mg/（m2·d）,第1天、第8天,每21天为一个周期]联合铂类药物方案化疗,至少2个周期后评价疗效。【结果】38例患者平均接受3.3（1-20）个周期治疗,客观有效率为13.8%（初治与复治患者分别为20.0%和7.1%）,疾病控制率为75.9%,中位无进展生存期（PFS）为4.0（1.0-25.0）月,总生存期（OS）是9.0（1.0-27.0）月。初治与复治患者PFS、OS无显著性差异。常见的不良反应是骨髓抑制（57.9%）、胃肠道反应（44.7%）及脱发（100.0%）。3/4度不良反应为骨髓抑制（21.1%）及胃肠道反应（2.6%）。【结论】白蛋白结合型紫杉醇联合铂类药物治疗晚期黑色素瘤疗效确切,耐受性良好。
【Objective】 To evaluate the efficacy and safety of nab-paclitaxel combined with platinum in Chinese patients with advanced malignant melanoma. 【Methods】 Patients with histologically confirmed, measurable advanced malignant melanoma received combined chemotherapy of nab-paclitaxel and a platinum agent. Nab-paclitaxel was administered intravenously weekly for 2 of 3 weeks at a dose of 100 mg / m2. Objective response was evaluated after every 2 cycles. 【Results】 38 patients were enrolled. The median number of treatment cycles was 3.3. The objective response rate was 13.8%（20.0% in the chemotherapy-naive cohort and 7.1% in the previously treated cohort） and the disease control rate was 75.9%. The median progression-free survival and overall survival were 4.0months and 9.0 months, respectively. The most common adverse events were myelosuppression（57.9%）, gastrointestinal reaction（44.7%）, and alopecia（100.0%）. 8（21.1%） patients experienced grade 3 / 4 myelosuppression and 1（2.6%） instance of grade 3diarrhea was documented. 【Conclusion】 The combination of nab-paclitaxel and platinum was found to be well tolerated and demonstrated activity in Chinese patients with advanced malignant melanoma.
出处
《中山大学学报（医学科学版）》
CAS
CSCD
北大核心
2015年第5期683-688,共6页
Journal of Sun Yat-Sen University:Medical Sciences
基金
国家自然科学基金(81272341)
